
Patent claims

1. Sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate corresponding to the compound of the formula (II)



(II)

2. Compound of the formula (II) according to Claim 1, characterized in that the compound of the formula (II) is present in crystalline form.

3. Process for preparing the compound of the formula (II) according to Claim 1, characterized in that the compound of the formula (I)



(Ia) (I) (Ib)

is reacted in a solvent with sodium hydroxide or aqueous sodium hydroxide solution or a sodium salt, if appropriate with addition of a base.

4. Process for preparing the compound of the formula (II) according to Claim 3, characterized in that the compound of the formula (I) is reacted in a solvent with aqueous sodium hydroxide solution, if appropriate with addition of a base.

5. Process for preparing the compound of the formula (II) according to Claim 3, characterized in that the compound of the formula (I) is reacted in a solvent with aqueous sodium hydroxide solution with addition of triethylamine.

6. Compound according to Claim 1 or 2 for the treatment and/or prophylaxis of diseases.

7. Use of the compound according to Claim 1 or 2 for the preparation of a medicament for treatment and/or prophylaxis of diseases.

8. Use of the compound according to Claim 1 or 2 for the preparation of a medicament for treatment and/or prophylaxis of cardiovascular diseases, cardiac insufficiency, anaemia, chronic kidney diseases and renal insufficiency.


9. Medicament comprising the compound according to Claim 1 or 2 in combination with an inert, non-toxic, pharmaceutically suitable auxiliary.

10. Medicament comprising the compound according to Claim 1 or 2 in combination with a further active compound.

11. Medicament according to Claim 9 or 10 for the treatment and/or prophylaxis of cardiovascular diseases, cardiac insufficiency, anaemia, chronic kidney diseases and renal insufficiency.

CLAIMS


1. Sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate corresponding to the compound of the formula (II)



(II)

2. Compound of the formula (II) according to claim 1, wherein the compound of the formula (II) is present in crystalline form.

3. Process for preparing the compound of the formula (II) according to claim 1, comprising reacting the compound of the formula (I)



(Ia) (I) (Ib)

in a solvent with sodium hydroxide or aqueous sodium hydroxide solution or a sodium salt, optionally with the addition of a base.

4. Process for preparing the compound of the formula (II) according to claim 3, comprising reacting the compound of the formula (I) in a solvent with aqueous sodium hydroxide solution, optionally with the addition of a base.

5. Process for preparing the compound of the formula (II) according to claim 3, comprising reacting the compound of the formula (I) in a solvent with aqueous sodium hydroxide solution with the addition of triethylamine.

6. A pharmaceutical composition comprising the compound according to claim 1 in combination with an inert, non-toxic, pharmaceutically suitable auxiliary.

7. A pharmaceutical composition comprising the compound according to claim 1 in combination with a further active compound.

8. A pharmaceutical composition comprising the compound according to claim 2 in combination with an inert, non-toxic, pharmaceutically suitable auxiliary.

9. A pharmaceutical composition comprising the compound according to claim 2 in combination with a further active compound.